REPLIGEN CORP (RGEN) Stock Fundamental Analysis

NASDAQ:RGEN • US7599161095

136.44 USD
+3.81 (+2.87%)
At close: Feb 13, 2026
136.44 USD
0 (0%)
After Hours: 2/13/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to RGEN. RGEN was compared to 58 industry peers in the Life Sciences Tools & Services industry. RGEN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. RGEN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • RGEN had positive earnings in the past year.
  • In the past year RGEN had a positive cash flow from operations.
  • RGEN had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years RGEN had a positive operating cash flow.
RGEN Yearly Net Income VS EBIT VS OCF VS FCFRGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

  • RGEN's Return On Assets of 0.06% is fine compared to the rest of the industry. RGEN outperforms 67.24% of its industry peers.
  • RGEN has a Return On Equity of 0.08%. This is in the better half of the industry: RGEN outperforms 68.97% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 1.05%, RGEN is in line with its industry, outperforming 58.62% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for RGEN is significantly below the industry average of 12.42%.
Industry RankSector Rank
ROA 0.06%
ROE 0.08%
ROIC 1.05%
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
RGEN Yearly ROA, ROE, ROICRGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 4 6 8

1.3 Margins

  • The Profit Margin of RGEN (0.25%) is better than 67.24% of its industry peers.
  • Looking at the Operating Margin, with a value of 6.58%, RGEN is in the better half of the industry, outperforming 60.34% of the companies in the same industry.
  • RGEN's Operating Margin has declined in the last couple of years.
  • RGEN's Gross Margin of 51.59% is in line compared to the rest of the industry. RGEN outperforms 58.62% of its industry peers.
  • RGEN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 6.58%
PM (TTM) 0.25%
GM 51.59%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
RGEN Yearly Profit, Operating, Gross MarginsRGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RGEN is destroying value.
  • The number of shares outstanding for RGEN has been increased compared to 1 year ago.
  • Compared to 5 years ago, RGEN has more shares outstanding
  • RGEN has a better debt/assets ratio than last year.
RGEN Yearly Shares OutstandingRGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
RGEN Yearly Total Debt VS Total AssetsRGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • RGEN has an Altman-Z score of 6.23. This indicates that RGEN is financially healthy and has little risk of bankruptcy at the moment.
  • RGEN has a Altman-Z score of 6.23. This is amongst the best in the industry. RGEN outperforms 87.93% of its industry peers.
  • RGEN has a debt to FCF ratio of 5.05. This is a neutral value as RGEN would need 5.05 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 5.05, RGEN is doing good in the industry, outperforming 67.24% of the companies in the same industry.
  • RGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of RGEN (0.26) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.05
Altman-Z 6.23
ROIC/WACC0.1
WACC10.37%
RGEN Yearly LT Debt VS Equity VS FCFRGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 8.36 indicates that RGEN has no problem at all paying its short term obligations.
  • RGEN's Current ratio of 8.36 is amongst the best of the industry. RGEN outperforms 91.38% of its industry peers.
  • A Quick Ratio of 7.14 indicates that RGEN has no problem at all paying its short term obligations.
  • RGEN's Quick ratio of 7.14 is amongst the best of the industry. RGEN outperforms 89.66% of its industry peers.
Industry RankSector Rank
Current Ratio 8.36
Quick Ratio 7.14
RGEN Yearly Current Assets VS Current LiabilitesRGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • RGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.17%, which is quite impressive.
  • The Earnings Per Share has been growing slightly by 7.11% on average over the past years.
  • The Revenue has decreased by -8.54% in the past year.
  • RGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.62% yearly.
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%

3.2 Future

  • Based on estimates for the next years, RGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 24.54% on average per year.
  • Based on estimates for the next years, RGEN will show a quite strong growth in Revenue. The Revenue will grow by 15.92% on average per year.
EPS Next Y14.82%
EPS Next 2Y19.82%
EPS Next 3Y22.25%
EPS Next 5Y24.54%
Revenue Next Year15.61%
Revenue Next 2Y14.01%
Revenue Next 3Y14.34%
Revenue Next 5Y15.92%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RGEN Yearly Revenue VS EstimatesRGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B 2.5B
RGEN Yearly EPS VS EstimatesRGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 82.19 indicates a quite expensive valuation of RGEN.
  • RGEN's Price/Earnings is on the same level as the industry average.
  • RGEN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.97.
  • RGEN is valuated quite expensively with a Price/Forward Earnings ratio of 64.21.
  • The rest of the industry has a similar Price/Forward Earnings ratio as RGEN.
  • RGEN is valuated expensively when we compare the Price/Forward Earnings ratio to 27.96, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 82.19
Fwd PE 64.21
RGEN Price Earnings VS Forward Price EarningsRGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • RGEN's Enterprise Value to EBITDA is on the same level as the industry average.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as RGEN.
Industry RankSector Rank
P/FCF 72.13
EV/EBITDA 65.38
RGEN Per share dataRGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • RGEN's earnings are expected to grow with 22.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)5.55
PEG (5Y)11.57
EPS Next 2Y19.82%
EPS Next 3Y22.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for RGEN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

REPLIGEN CORP

NASDAQ:RGEN (2/13/2026, 8:00:01 PM)

After market: 136.44 0 (0%)

136.44

+3.81 (+2.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-28
Earnings (Next)02-24
Inst Owners110.6%
Inst Owner Change0.9%
Ins Owners0.45%
Ins Owner Change-2.86%
Market Cap7.68B
Revenue(TTM)707.89M
Net Income(TTM)1.74M
Analysts81.43
Price Target194.44 (42.51%)
Short Float %7.48%
Short Ratio6.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.48%
Min EPS beat(2)-6.83%
Max EPS beat(2)7.78%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-6.83%
Max EPS beat(4)10.73%
EPS beat(8)4
Avg EPS beat(8)4.05%
EPS beat(12)8
Avg EPS beat(12)8.34%
EPS beat(16)12
Avg EPS beat(16)11.45%
Revenue beat(2)2
Avg Revenue beat(2)2.11%
Min Revenue beat(2)2.07%
Max Revenue beat(2)2.15%
Revenue beat(4)3
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)2.15%
Revenue beat(8)3
Avg Revenue beat(8)-0.3%
Revenue beat(12)3
Avg Revenue beat(12)-1%
Revenue beat(16)7
Avg Revenue beat(16)0.58%
PT rev (1m)0.71%
PT rev (3m)7.02%
EPS NQ rev (1m)0.29%
EPS NQ rev (3m)0.05%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)-0.2%
Revenue NQ rev (1m)0.1%
Revenue NQ rev (3m)0.1%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)0.31%
Valuation
Industry RankSector Rank
PE 82.19
Fwd PE 64.21
P/S 10.85
P/FCF 72.13
P/OCF 58.68
P/B 3.69
P/tB 13.36
EV/EBITDA 65.38
EPS(TTM)1.66
EY1.22%
EPS(NY)2.12
Fwd EY1.56%
FCF(TTM)1.89
FCFY1.39%
OCF(TTM)2.33
OCFY1.7%
SpS12.58
BVpS37.01
TBVpS10.21
PEG (NY)5.55
PEG (5Y)11.57
Graham Number37.18
Profitability
Industry RankSector Rank
ROA 0.06%
ROE 0.08%
ROCE 1.67%
ROIC 1.05%
ROICexc 1.43%
ROICexgc 5.46%
OM 6.58%
PM (TTM) 0.25%
GM 51.59%
FCFM 15.04%
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexgc growth 3Y-71.22%
ROICexgc growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score6
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.05
Debt/EBITDA 4.85
Cap/Depr 37.9%
Cap/Sales 3.45%
Interest Coverage 250
Cash Conversion 117.95%
Profit Quality 6126.58%
Current Ratio 8.36
Quick Ratio 7.14
Altman-Z 6.23
F-Score6
WACC10.37%
ROIC/WACC0.1
Cap/Depr(3y)91.1%
Cap/Depr(5y)111.21%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
EPS Next Y14.82%
EPS Next 2Y19.82%
EPS Next 3Y22.25%
EPS Next 5Y24.54%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
Revenue Next Year15.61%
Revenue Next 2Y14.01%
Revenue Next 3Y14.34%
Revenue Next 5Y15.92%
EBIT growth 1Y163.23%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year69.07%
EBIT Next 3Y37.02%
EBIT Next 5Y34.76%
FCF growth 1Y9.1%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-10.84%
OCF growth 3Y13.8%
OCF growth 5Y21.15%

REPLIGEN CORP / RGEN FAQ

Can you provide the ChartMill fundamental rating for REPLIGEN CORP?

ChartMill assigns a fundamental rating of 5 / 10 to RGEN.


What is the valuation status for RGEN stock?

ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.


What is the profitability of RGEN stock?

REPLIGEN CORP (RGEN) has a profitability rating of 4 / 10.


What is the financial health of REPLIGEN CORP (RGEN) stock?

The financial health rating of REPLIGEN CORP (RGEN) is 7 / 10.


What is the earnings growth outlook for REPLIGEN CORP?

The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 14.82% in the next year.